Chronic Kidney Disease

The Kidney Transplant Fast Track evaluation approach was associated with a higher likelihood of waitlisting and fewer disparities by race or ethnicity.

Psychosocial interventions reduced depressive symptoms in CKD but did not have a significant impact on patients’ quality of life.

Our top 5 headlines include 5 key FDA decisions, including the first approval for stroke in 3 decades, an expanded indication for pediatric anaphylaxis, and more!

Kidney transplant recipients who received a GLP-1 RA had a 49% lower incidence of death-censored graft loss and 31% lower mortality.

The FDA approved the sNDA for furosemide (Furoscix) to expand the indication to include treatment of edema in patients with CKD.

In part 2 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss strategies to address the CKD crisis.

In part 1 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss CKD’s emergence as a public health crisis.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.

The guidance is intended to inform the transition to outpatient care for patients with AKI-D and help care teams identify early signs of recovery.

Survey findings highlight pediatric nephrologists’ reluctance to list patients with kidney failure due to C3G or IC-MPGN for kidney transplantation.

From 1990-2021, the ASIR, ASMR, and age-standardized DALY rate of chronic kidney disease increased.

Female dialysis patients had a greater risk of infection- and withdrawal-related mortality, while men were more likely to die from cardiovascular disease and cancer.

Greater levels of RC were linked to increased CKD risk and progression to ESRD in patients with type 2 diabetes-related kidney disease.

Findings highlight the need for early frailty screening in dialysis patients and the implementation of appropriate interventions to improve outcomes.

Data from the phase 1 trial are intended to support dosing in a planned phase 2 trial in kidney transplant recipients.

Completion of the trial was announced in a financial update from Novo Nordisk, who explained the trial missed its primary endpoint for uACR improvement.

Findings call attention to age-related neurodevelopmental differences between pediatric patients with CKD and healthy controls.

United Therapeutics’ investigational UKidney is derived from a 10 gene-edited source pig and will be tested in a clinical study of ESRD patients.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

In this episode, hosts discuss the approval of semaglutide (Ozempic) for reducing the progression of kidney disease in type 2 diabetes.

Garimella describes the overlap between diabetes and kidney disease, explaining the significance of semaglutide’s new indication for these patients.

Findings suggest the benefits of combined belatacept and tacrolimus immunosuppression after kidney transplantation for patient and all-cause graft survival.

The FDA approved semaglutide to reduce the risk of kidney disease worsening, kidney failure, and death due to CVD in those with T2D and CKD.

Patients who started dialysis as children but were not waitlisted until young adulthood faced worse outcomes than those who were listed before turning 18.

Donor HCV positivity was not associated with acute rejection or recipient mortality 1-year post-renal transplant in HCV-negative recipients.